ArticleInternational urology and nephrology2026
Serum sclerostin in biopsy-proven glomerulonephritis primarily reflects kidney function: a cross-sectional case-control study.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSclerostin, an osteocyte-derived Wnt/β-catenin inhibitor, increases with declining kidney function and is implicated in chronic kidney disease-mineral and bone disorder (CKD-MBD). Whether circulating sclerostin reflects disease-specific activity in biopsy-proven glomerulonephritis (GN), independent of renal function and demographic confounders, remains unclear.
methodsIn a single-centre cross-sectional case-control study, 49 adults with biopsy-proven GN and 30 healthy controls were enrolled. Serum sclerostin was measured by enzyme-linked immunosorbent assay (ELISA). Its associations with kidney function (estimated glomerular filtration rate, eGFR), proteinuria and routine biochemical parameters were examined using non-parametric tests and multivariable linear regression adjusted for age, sex and eGFR. To address baseline differences between groups and to test whether kidney function explained the observed associations, we additionally performed a propensity-score-weighted sensitivity analysis and a mediation-style statistical decomposition, with correction for multiple comparisons.
resultsGN patients were older, more often male and had lower eGFR than controls. Serum sclerostin was higher in GN patients than in controls in the unadjusted comparison (median 10.86 vs 7.14 ng/mL, p < 0.001). However, this difference progressively weakened after accounting for age and sex, and was no longer statistically significant once kidney function (eGFR) was taken into account. The propensity-score-weighted sensitivity analysis showed the same pattern. Within the GN group, higher sclerostin was strongly associated with lower kidney function, and this relationship persisted in adjusted models. The apparent link between sclerostin and proteinuria was likewise explained mainly by kidney function: about three-quarters of the crude association was accounted for by the eGFR pathway (indirect effect 0.71; 95% confidence interval [95% CI] 0.16 to 1.54). Sclerostin was not robustly associated with the inflammatory markers C-reactive protein or ferritin, and an isolated inverse association with fibrinogen was regarded as exploratory because fibrinogen was measured in only 13 patients.
conclusionsIn biopsy-proven GN, elevated circulating sclerostin primarily reflects differences in kidney function, age and sex rather than GN-specific activity; within the limits of a healthy-control rather than CKD-control comparison, the data do not support serum sclerostin as an independent biomarker of glomerular disease activity. Prospective studies with non-GN CKD comparators and a complete CKD-MBD panel are needed.
Indexed as
Identifiers
42423954What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.